Axim Biotechnologies, Inc. (AXIM) Stock Price & Analysis

Axim Biotechnologies, Inc. (AXIM) rose 0.00% to USD 0 as of July 25, 2026 at 06:41 UTC, according to Nexqual real-time market data.

AXIM last closed at USD 0; the session ranged USD 0–0 on volume of 450,000 shares. Market capitalization is $1.02M, with a 52-week range of USD 0–0.03 (OID). Source: Nexqual, July 25, 2026 at 06:41 UTC.

Key Statistics (as of July 25, 2026 at 06:41 UTC)

Technical Analysis (AXIM)

Nexqual's technical model rates AXIM "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:41 UTC.

Analyst Ratings (AXIM)

Wall Street analysts rate AXIM "None", per Nexqual as of July 25, 2026 at 06:41 UTC.

Earnings (AXIM)

Source: Nexqual, July 25, 2026 at 06:41 UTC.

Financials & Fundamentals (AXIM)

Source: Nexqual, July 25, 2026 at 06:41 UTC.

Financial Health Score (AXIM)

Nexqual rates Axim Biotechnologies, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:41 UTC.

Ownership (AXIM)

Source: Nexqual, July 25, 2026 at 06:41 UTC.

Leadership (AXIM)

Axim Biotechnologies, Inc. is led by Catalina Valencia (age 75), CEO, President & Director, per Nexqual as of July 25, 2026 at 06:41 UTC.

From Axim Biotechnologies, Inc.'s Latest SEC 10-K Filing (filed 2024-04-16)

Key Strengths & Strategy (as disclosed to the SEC)

• The expected timeline for filing and receiving a final CLIA decision is approximately three to six months.   Patented Tear Collection System   Tear fluid analysis contributes to the greater understanding of various ocular and systemic diseases.
• Lower concentrations of Lacritin may diagnose several eye diseases, including Blepharitis, Sjögren's syndrome, Dry Eye Disease and other inflammatory conditions.   Tear Sample Collectors Systems and Methods. 1 Utility Patent Application   Tear fluid analysis contributes to the greater understanding of various ocular and systemic diseases and obtaining adequate samples for tear analysis requires effective collection methods.
• On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc.   The Company's historical business operations focused on the research, development and production of pharmaceutical, nutraceutical and cosmetic products based upon our proprietary technologies.
• AXIM's proprietary platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.   New Patent Allowances   AXIM was recently notified by the United States Patent & Trademark Office (USPTO) of three patent allowances.

Partnerships

• Shortly after its development, we filed for Emergency Use Authorization with the Food and Drug Administration (FDA), signed a distribution and manufacturing agreement, initiated live virus comparison studies, and filed several patent applications on the diagnostic tools.
• Our cutting-edge, next-generation solutions provide AXIM with far higher prospects of predictable growing revenue and earnings power.   On August 26, 2021, we signed an agreement to acquire two FDA-cleared 510(k)'s DED diagnostic testing technologies.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:41 UTC. This page is informational and not investment advice.